208 related articles for article (PubMed ID: 26675719)
1. Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.
Ulaganathan VK; Sperl B; Rapp UR; Ullrich A
Nature; 2015 Dec; 528(7583):570-4. PubMed ID: 26675719
[TBL] [Abstract][Full Text] [Related]
2. The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis.
Tateno T; Asa SL; Zheng L; Mayr T; Ullrich A; Ezzat S
PLoS Genet; 2011 Dec; 7(12):e1002400. PubMed ID: 22174695
[TBL] [Abstract][Full Text] [Related]
3. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
4. STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion.
Kogan D; Grabner A; Yanucil C; Faul C; Ulaganathan VK
J Clin Invest; 2018 May; 128(5):1867-1872. PubMed ID: 29438108
[TBL] [Abstract][Full Text] [Related]
5. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
[TBL] [Abstract][Full Text] [Related]
6. Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis.
Xiong SW; Ma J; Feng F; Fu W; Shu SR; Ma T; Wu C; Liu GC; Zhu J
Oncotarget; 2017 Apr; 8(15):25300-25309. PubMed ID: 28445975
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.
Zhu X; Zheng L; Asa SL; Ezzat S
Am J Pathol; 2010 Dec; 177(6):2860-9. PubMed ID: 21037081
[TBL] [Abstract][Full Text] [Related]
8. FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors.
Ezzat S; Wang R; Pintilie M; Asa SL
Oncotarget; 2017 Jan; 8(2):3481-3494. PubMed ID: 27966451
[TBL] [Abstract][Full Text] [Related]
9. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
Falvella FS; Frullanti E; Galvan A; Spinola M; Noci S; De Cecco L; Nosotti M; Santambrogio L; Incarbone M; Alloisio M; Calabrò E; Pastorino U; Skaug V; Haugen A; Taioli E; Dragani TA
Int J Cancer; 2009 Jun; 124(12):2880-5. PubMed ID: 19296538
[TBL] [Abstract][Full Text] [Related]
10. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression.
Stadler CR; Knyazev P; Bange J; Ullrich A
Cell Signal; 2006 Jun; 18(6):783-94. PubMed ID: 16109476
[TBL] [Abstract][Full Text] [Related]
11. Induction of Fibroblast Growth Factor Receptor 4 by Helicobacter pylori via Signal Transducer and Activator of Transcription 3 With a Feedforward Activation Loop Involving SRC Signaling in Gastric Cancer.
Zhang X; Soutto M; Chen Z; Bhat N; Zhu S; Eissmann MF; Ernst M; Lu H; Peng D; Xu Z; El-Rifai W
Gastroenterology; 2022 Sep; 163(3):620-636.e9. PubMed ID: 35588797
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of IL6ST (gp130) mutations in exon 6 in lung cancer of a Chinese cohort.
Sun L; Sui L; Cong X; Ma K; Ma X; Huang Y; Fan C; Fu X; Ma K
Cancer Genet; 2014; 207(7-8):291-8. PubMed ID: 25242236
[TBL] [Abstract][Full Text] [Related]
13. The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes.
Ezzat S; Zheng L; Florez JC; Stefan N; Mayr T; Hliang MM; Jablonski K; Harden M; Stančáková A; Laakso M; Haring HU; Ullrich A; Asa SL
Cell Metab; 2013 Jun; 17(6):929-940. PubMed ID: 23747250
[TBL] [Abstract][Full Text] [Related]
14. Re-evaluating the FGFR4 (G388R) germline mutation in different cancers in Pakistani population.
Mansoor Q; Fayyaz S; Farooqi AA; Bhatti S; Ismail M
J Exp Ther Oncol; 2013; 10(3):215-7. PubMed ID: 24416997
[TBL] [Abstract][Full Text] [Related]
15. FGFR4 polymorphic variants modulate phenotypic features of Cushing disease.
Nakano-Tateno T; Tateno T; Hlaing MM; Zheng L; Yoshimoto K; Yamada S; Asa SL; Ezzat S
Mol Endocrinol; 2014 Apr; 28(4):525-33. PubMed ID: 24625004
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
Marks JL; McLellan MD; Zakowski MF; Lash AE; Kasai Y; Broderick S; Sarkaria IS; Pham D; Singh B; Miner TL; Fewell GA; Fulton LL; Mardis ER; Wilson RK; Kris MG; Rusch VW; Varmus H; Pao W
PLoS One; 2007 May; 2(5):e426. PubMed ID: 17487277
[TBL] [Abstract][Full Text] [Related]
18. Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variants.
Ulaganathan VK; Ullrich A
Mol Cell Oncol; 2016 May; 3(3):e1145176. PubMed ID: 27314095
[TBL] [Abstract][Full Text] [Related]
19. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
Taylor JG; Cheuk AT; Tsang PS; Chung JY; Song YK; Desai K; Yu Y; Chen QR; Shah K; Youngblood V; Fang J; Kim SY; Yeung C; Helman LJ; Mendoza A; Ngo V; Staudt LM; Wei JS; Khanna C; Catchpoole D; Qualman SJ; Hewitt SM; Merlino G; Chanock SJ; Khan J
J Clin Invest; 2009 Nov; 119(11):3395-407. PubMed ID: 19809159
[TBL] [Abstract][Full Text] [Related]
20. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.
Matakidou A; El Galta R; Rudd MF; Webb EL; Bridle H; Eisen T; Houlston RS
Br J Cancer; 2007 Jun; 96(12):1904-7. PubMed ID: 17519899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
